Related Experiment Video
Updated: May 9, 2026
06:03
Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
Published on: September 30, 2021
[Chemotherapy for GI and pancreatic NETs].
1Dept. of GI oncology and Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 19, 2013
Summary
Neuroendocrine tumors (NETs) are a diverse group of cancers. Pancreatic neuroendocrine tumors (pNETs), a subset of NETs, are increasing and can be life-threatening when advanced, but new targeted therapies offer improved outcomes.
Area of Science:
- Oncology
- Endocrinology
- Pathology
Context:
- Neuroendocrine tumors (NETs) represent a heterogeneous cancer classification.
- Pancreatic neuroendocrine tumors (pNETs) are a specific subtype of NETs with rising incidence and prevalence.
- While often indolent, metastatic pNETs pose significant therapeutic challenges.
Purpose:
- To review the evolving landscape of pancreatic neuroendocrine tumor (pNET) treatment.
- To highlight recent advancements in targeted therapies for pNETs.
- To discuss the potential of combination therapies for improved patient outcomes.
Summary:
- Pancreatic neuroendocrine tumors (pNETs) are increasingly diagnosed and present a therapeutic challenge, particularly in advanced stages.
- The recent approval of targeted agents like sunitinib and everolimus marks a significant shift in pNET management.
- Ongoing clinical trials explore combinations of somatostatin analogues, mTOR inhibitors, tyrosine kinase inhibitors, and cytotoxic agents.
Impact:
- New targeted therapies are transforming the treatment paradigm for pancreatic neuroendocrine tumors.
- A multitargeted therapeutic approach is anticipated to enhance patient outcomes in pNET management.
- Advances in understanding and treating pNETs are crucial for improving survival and quality of life.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:15Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...